FACOG

ARC Fertility Named Finalist for Two Categories at FemTech World Awards 2024

Retrieved on: 
星期二, 五月 7, 2024
Other Health, Professional Services, LGBTQ+, Consumer, HVAC, Hospitals, Health Insurance, Baby, Maternity, Women, Insurance, Manufacturing, Health, FACS, FRCSC, Femtech, Fertility, MD, FACOG, Patient, ARC, Wellbeing of Women

ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly announces its selection as a finalist in two categories at the recently held prestigious FemTech World Awards 2024 ceremony.

Key Points: 
  • ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly announces its selection as a finalist in two categories at the recently held prestigious FemTech World Awards 2024 ceremony.
  • The FemTech Awards, recognizing outstanding achievements in women's health technology, shortlisted ARC for the "Company of the Year," sponsored by Guidea and "Gender Inclusive Employer," sponsored by Wellbeing of Women.
  • “Our FertilityNow app exemplifies the ability of FemTech to empower patients by providing a user-friendly platform that facilitates informed decision-making and personalized fertility journeys,” says Dr. Adamson.
  • “Through a strategic fusion of personalized care, virtual accessibility, evidence-based practices, user-friendly interfaces and cutting-edge apps, ARC Fertility continues to redefine the future of reproductive care in a concise and impactful manner.”

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
星期六, 五月 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

March of Dimes Launches Low Dose, Big Benefits™ Campaign to Combat Preeclampsia and Preterm Birth

Retrieved on: 
星期三, 五月 1, 2024
Education, Mortality, Element, Preterm birth, Risk, Vaccine, Philips Avent, Diagnosis, Death, FACOG, Knowledge, Pregnancy, Woman, CDC, The Harris Poll, Infant, Black, Stanford University, Faculty, Pharmacist, Media, Partner, Fear, Aspirin, Health, The Honest Company, Research, Pre-eclampsia, Mental health, MPH, Medicine, Biology, Disease, Society, Blood pressure, Quality, HCA Healthcare, IHeartRadio, Initiative, Patient, Hypertension, MBA, Birth control

ARLINGTON, Va., May 1, 2024 /PRNewswire/ -- March of Dimes, the leading organization fighting for the health of all moms and babies, today announced the launch of Low Dose, Big Benefits, a multi-year campaign aimed at decreasing the adverse effects of preeclampsia and preterm birth through the use of low dose aspirin. The new campaign will feature US Olympian and Entrepreneur Allyson Felix as a brand ambassador and is part of the March of Dimes' It Starts With Mom platform, which provides families with educational information and resources during their pregnancy journey. It Starts With Mom is generously supported by trusted partners, including HCA Healthcare, Clearblue, Goldbug, The Honest Company, Philips Avent, and Sanofi.

Key Points: 
  • Preeclampsia is a potentially fatal condition that causes a pregnant woman's blood pressure to rise and can lead to preterm birth, heart disease, and other complications.
  • Studies show that pregnant people at an increased risk for preeclampsia who take low dose aspirin may reduce their risk of preeclampsia by 15% and their risk of preterm birth by 20%.
  • Low Dose, Big Benefits is the culmination of March of Dimes' legacy since 1938 of funding research to help millions of babies survive and thrive.
  • The organization went on to create the Prematurity Campaign Roadmap in 2015 that identified eight interventions that could reduce the preterm birth rate and included low dose aspirin.

Xavier Ochsner College of Medicine Announces Founding Dean and Location in Downtown New Orleans at Benson Tower

Retrieved on: 
星期一, 四月 29, 2024
Education, Health equity, Biomedical Research, Partnership, Blessed Sacrament, SACSCOC, Culture, Morehouse School of Medicine, Accreditation, Medicine, Lead, HBCU, FACOG, Knowledge, Ochsner Health System, Xavier University of Louisiana, Meharry Medical College, Black, JD, Liaison Committee, Workforce, Caesars Superdome, Xavier University, Health, Katharine Drexel, Trustee, Medical education, Treatment, RN, Multimedia, Student, Benson Tower, MAS, Ochsner, National library, MD, Associate professor, History, Curriculum, Friends, Senior, Physician, LCME, College, Economic development, FACP, Nursing

NEW ORLEANS, April 29, 2024 /PRNewswire/ -- Xavier University of Louisiana (Xavier), a leading undergraduate institution in preparing Black students to successfully complete medical school, has announced continued progress with Ochsner Health (Ochsner), the Gulf South's leading academic medical center in training physicians, to launch their transformational Xavier Ochsner College of Medicine (XOCOM). This groundbreaking partnership marks a significant milestone in advancing medical education by addressing health disparities in diverse communities and helping fulfill the urgent need for more physicians in Louisiana and the nation. The new medical school will be in the burgeoning BioDistrict New Orleans, located downtown in Benson Tower next to Caesars Superdome.

Key Points: 
  • The new medical school will be in the burgeoning BioDistrict New Orleans , located downtown in Benson Tower next to Caesars Superdome.
  • "Xavier Ochsner College of Medicine was born from a truly collaborative vision between Xavier University of Louisiana and Ochsner Health.
  • When it opens, the Xavier Ochsner College of Medicine will join the nation's four existing historically Black medical schools : Howard University College of Medicine, Morehouse School of Medicine, Meharry Medical College, and the Charles R. Drew University of Medicine and Science.
  • By anchoring their partnership with the Xavier Ochsner College of Medicine (XOCOM), Xavier and Ochsner will advance healthcare excellence, bring new opportunities to marginalized populations and create stellar medical education for future generations.

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Retrieved on: 
星期二, 四月 16, 2024
Patient, DiGeorge syndrome, American College, MYGN, Pregnancy, Test management, Myriad Genetics, Ventricular septal defect, FACMG, MD, Doctor of Philosophy, Genetic testing, Medical genetics, Genetics, DNA, SNP, PPV, Genomics, Medicine, FACOG, Dietary supplement

“This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.

Key Points: 
  • “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
  • This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
  • 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
  • The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.

New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women

Retrieved on: 
星期三, 五月 1, 2024
Women, Biotechnology, Surgery, Health, Baby, Maternity, Hospitals, Consumer, Other Health, Patient, Risk, Pregnancy, Aspirin, MD, Survivor, Disease, Obesity, Exercise, Pre-eclampsia, Cardiovascular disease, FACOG, Birth control

As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.

Key Points: 
  • As May marks Preeclampsia Awareness Month , leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “ Preeclampsia Prevention is Possible .” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.
  • “Preeclampsia is often viewed as a complication with limited ability to intervene early and lower the risk of developing the condition,” said Eleni Tsigas, CEO of the Preeclampsia Foundation and preeclampsia survivor.
  • “However, all year long, and especially during Preeclampsia Awareness Month, we’re amplifying the message that we are in an era where we can better predict, prevent, and prevail over the adverse outcomes caused by preeclampsia.
  • “With objective, personalized data, pregnant patients can finally know their risk, create a plan and work with their care team to take every possible measure to prevent preeclampsia.”
    Patients and providers can access the educational toolkit at PreeclampsiaPrevention.com .

ARC Fertility Captures Validation Institute 2023 Award for Cost Savings Report, Hosts Webinar

Retrieved on: 
星期二, 四月 30, 2024
Other Health, Professional Services, LGBTQ+, Consumer, Hospitals, Advocacy Group Opinion, Parenting, Health Insurance, Baby, Maternity, Insurance, Health, Public Policy, Government, Fertility, Twin, ARC, MD, Parent, Level 1, FACS, FRCSC, Patient, Validation, Mother, FACOG, Woman, Nursing

ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly announces its recognition by the Validation Institute with the 2023 Award for its exceptional cost savings report.

Key Points: 
  • ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly announces its recognition by the Validation Institute with the 2023 Award for its exceptional cost savings report.
  • In conjunction with this achievement, David Adamson, MD, FRCSC, FACOG, FACS, Founder and CEO, ARC Fertility, will be presenting a webinar with the Validation Institute on Tuesday, May 7, 2023, at 1:00 pm ET.
  • "Receiving the Validation Institute 2023 Award underscores our dedication to delivering tangible results and cost savings for employers and families," says Dr. Adamson.
  • The Validation Institute awarded ARC Fertility the prestigious Level 1 validation for savings achieved, validating the effectiveness of its infertility care.

New Report Reveals that 9 out of 10 New Mothers Returning to Work Face At Least One Major Challenge That Threatens Career Success

Retrieved on: 
星期二, 四月 30, 2024
Pregnancy, Woman, DKC, Health, Maternal health, Workplace, Parent, Transport, White, Family, Mental health, MPH, Child care, Face, Workforce, Mother, FACOG, Meditation, Ageing, Birth control

MENLO PARK, Calif., April 30, 2024 /PRNewswire/ -- According to recent data, there are more mothers of young children in the workforce now than pre-pandemic. While this progress is promising, women in the workforce face significant challenges throughout their pregnancy and postpartum journeys, according to a new Maternal Health in the Workplace report from Carrot Fertility. As the leading global fertility and family-building platform, the company commissioned a survey of 1,260 women in the U.S. to understand the full impact of the pregnancy journey – from prenatal preparedness to return to work – on mothers in the workplace. The results highlight specific obstacles they face and the need for more comprehensive maternal health support.

Key Points: 
  • The report also highlighted consistent racial disparities across many areas of maternal care, with preparedness for Black and Hispanic mothers falling behind other groups at each stage.
  • In fact, 34% of Hispanic mothers are dissatisfied with their medical care during the return-to-work phase, compared to 21% of white mothers.
  • Black mothers (37%) and Asian mothers (43%) most often report not knowing where to find support.
  • Nearly all mothers (91%) cited at least one major challenge returning to work, including child care (35%), balancing workload with other demands (32%), and continued career advancement (30%).

Latino Physicians and Medical Professionals Gather to Talk Diversity Initiatives and the Future of Latino Healthcare

Retrieved on: 
星期四, 四月 11, 2024
Obesity medicine, MACP, Health equity, AIDS, Health, White, Senior, Legislation, MPH, Physician, MBA, FACOG

The 30th Anniversary and Leadership Summit will feature over 30 keynote speakers from numerous facets of the healthcare industry, including advanced education, industry-leading research, rising medical residents, and practicing physicians.

Key Points: 
  • The 30th Anniversary and Leadership Summit will feature over 30 keynote speakers from numerous facets of the healthcare industry, including advanced education, industry-leading research, rising medical residents, and practicing physicians.
  • The "40 Under 40" campaign spotlights individuals who demonstrated extraordinary dedication, exemplary leadership, and profound contributions to advancing health equity.
  • These rising stars will be celebrated for their commitment to improving healthcare outcomes for Hispanic communities.
  • Selected honorees will be recognized at NHMA and NHHF's 30th Anniversary Gala on Saturday.

GTG to pilot GeneType in Breast Screen centers across the U.S.

Retrieved on: 
星期四, 四月 11, 2024
Breast cancer, Breast, GTG, Risk, Woman, Montefiore Medical Center, Health, Radar, Florida International University, Communication, ASX, FACS, Patient, Medicine, Breast cancer screening, Risk assessment, Mount Sinai Medical Center, FACOG, Medical imaging

The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.

Key Points: 
  • The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.
  • Risk-stratified Decision-Making: By integrating the geneType Breast Cancer Risk Assessment Test into breast imaging centers, patients at higher risk of breast cancer can be easily identified during imaging appointments.
  • Implementation of GeneType: Collaborating with leading breast imaging centers will provide an excellent opportunity for integrating geneType in a high throughput clinical scenario.
  • Its integration into breast imaging centers marks a significant shift in how breast cancer risk is evaluated.